Janus Henderson offers sustainability, biotechnology funds in Singapore
The global sustainability and biotechnology funds will include healthcare and ESG portfolios for retail investors
Global asset manager Janus Henderson Investors has registered the Janus Henderson Horizon Global Sustainable Equity Fund and Janus Henderson Horizon Biotechnology Fund for sale to retail investors in Singapore.
“Our funds are managed by some of the most experienced teams in their respective fields. We are confident that they will play key roles in our clients’ portfolios, be it a solution to tap into US healthcare innovation or a way to grow wealth while doing good,” says Scott Steele, head of distribution, Asia.
Powerful environmental and social trends are going to transform the global economy over coming decades. The Janus Henderson Horizon Global Sustainable Equity Fund invests with the belief that the best investment returns will be generated by companies which provide solutions to environmental and social challenges.
Hamish Chamberlayne is the lead portfolio manager and has managed the strategy since December 2011. The new fund will utilize the same investment approach as the existing UK domiciled Global Sustainable Equity OEIC.
The team’s investment approach is explicitly low carbon and by incorporating environmental, social and governance (ESG) factors into their analysis they seek to construct a portfolio with a favourable risk profile.
“We believe that an SRI approach should not compromise the potential to provide positive returns through a differentiated global equity portfolio of the best sustainability ideas. Our strategy is designed to invest in businesses that are strategically aligned with the environmental and social trends that are changing the shape of the global economy,” says Hamish Chamberlayne, head of Sustainable, Responsible and Impact, investing (SRI).
The Janus Henderson Horizon Biotechnology Fund invests in innovative biotechnology and biotechnology-related companies that seek to address high unmet medical needs around the world. It is co-managed by Andy Acker and Dan Lyons, who have more than 40 years of combined experience investing in biotechnology.
The success of drug development is binary in nature, creating wide disparities between winners and losers. The team uses its proprietary statistical models and scientific expertise to analyze the probability of success for drugs in clinical development. The team also integrates the perspectives of physicians, patients, and payers to evaluate the commercial prospects for new and existing therapies.
The fund invests at least 80% of its assets in biotechnology and biotechnology-related companies worldwide. This includes companies in the NASDAQ Biotechnology Total Return index, those that develop small molecule or biologic drugs subject to approval of regulatory agencies, and firms that market products and services that aid in the research and development of small molecule or biologic drugs.
“The pace of progress in the biotechnology industry is accelerating, leading to more rapid medical breakthroughs. So far in 2018, the FDA has approved 55 new therapies – an all-time record. Our process focuses on the scientific and business drivers that are critical to mitigating the risks and uncovering the opportunities presented by this dynamic sector,” says Andy Acker.
Notably, the biotechnology fund is carved out of the successful Global Life Sciences Fund, which, in addition to biotechnology, also invests in other healthcare subsectors.
Both the Janus Henderson Horizon Global Sustainable Equity Fund and Janus Henderson Horizon Biotechnology Fund are Luxembourg-domiciled SICAV funds. The funds have been submitted to Securities and Futures Commission for consideration to be sold in Hong Kong.
Social Media Links (This section can be seen in office only):
Twitter : https://www.theasset.com/article-single.php?id=38627&social=twitter
Linkedin : https://www.theasset.com/article-single.php?id=38627&social=linkedin
Facebook : https://www.theasset.com/article-single.php?id=38627&social=facebook